PUBLICATIONS

[Selected]

Tan X, Xiao GY, Banerjee P, Wang S, Kurie JM. The cancer-associated secretory phenotype: a new frontier in targeted therapeutics. Journal of Clinical Investigation. 2024;134(17):e182652. [Link]

Tan X, Wang S, Xiao GY, Wu C, Liu X, Zhou B, Yu J, Duose DY, Xi Y, Wang J, Gupta K, Pataer A, Roth JA, Kim MP, Chen F, Creighton CJ, Russell WK, Kurie JM. Chromosomal 3q amplicon encodes essential regulators of secretory vesicles that drive secretory addiction in cancer. Journal of Clinical Investigation. 2024;134(12):e176355. [Link]

Xiao GY, Tan X, Rodriguez BL, Gibbons DL, Wang S, Wu C, Liu X, Yu J, Vasquez ME, Tran HT, Xu J, Russell WK, Haymaker C, Lee Y, Zhang J, Solis L, Wistuba II, Kurie JM. EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer. PNAS. 2023;120 (28): e2220276120. [Link]

  • This work demonstrates that the EMT-dependent metastasis, which was previously thought to be a cell-autonomous process, is also driven by a cell-non-autonomous mechanism. This discovery has significant implications for targeting secretory trafficking to prevent LUAD metastasis.

Tan X, Xiao GY, Wang S, Shi L, Zhao Y, Liu X, Yu J, Russell WK, Creighton CJ, Kurie JM. EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer. Journal of Clinical Investigation. 2023;133(7):e165863. [Link]

Banerjee P*, Xiao GY*, Tan X, Zheng VJ, Shi L, Rabassedas MNB, Guo HF, Liu X, Yu J, Diao L, Wang J, Russell WK, Roszik J, Creighton CJ, Kurie JM. The EMT activator ZEB1 accelerates endosomal trafficking to establish a polarity axis in lung adenocarcinoma cells. Nature Communication. 2021;12(1): 6354. *Co-first author. [Link] (cited by 7)

  • This work determines that EMT coordinates endocytic trafficking pathways via a transcriptional network to establish a polarity axis for lung cancer cell migration.

Xiao GY and Schmid SL. FCHSD2 controls oncogenic ERK1/2 signaling outcome by regulating endocytic trafficking. PLoS Biology. 2020;18(7): e3000778. [Link] (cited by 7)

  • This work elucidates that FCHSD2 functions as a key nexus in the outcome of oncogenic ERK1/2 signaling by controlling the trafficking and expression of EGFR and MET.

Xiao GY, Mohanakrishnan A, Schmid SL. ERK1/2-dependent activation of FCHSD2 drives cancer cell-selective regulation of clathrin-mediated endocytosis. PNAS. 2018;115(41): E9570-E9579. [Link] (cited by 25)

  • This work discovers the cancer-specific adaptions that oncogenic signaling kinases manage endocytic vesicle trafficking to control center progression.

Xiao GY, Cheng CC, Chiang YS, Cheng WTK, Liu IH, Wu SC. Exosomal miR-10a derived from amniotic fluid stem cells preserves ovarian follicles after chemotherapy. Scientific Reports. 2016;6: 23120. [Link] (cited by 126)

  • This work elucidates the therapeutic mechanisms that amniotic fluid stem cell-derived exosomal microRNAs exert anti-apoptotic effects on damaged ovarian cells. This landmark paper provided a novel strategy for ovarian failure therapy.

Xiao GY, Liu IH, Cheng CC, Chang CC, Lee YH, Cheng WTK, Wu SC. Amniotic fluid stem cells prevent follicle atresia and rescue fertility of mice with premature ovarian failure induced by chemotherapy. PLoS ONE. 2014;9: e106538. [Link] (cited by 90)

Complete list of published work in my bibliography:

https://www.ncbi.nlm.nih.gov/myncbi/1HYfd5TM3dBo9t/bibliography/public/